All Personalised Medicine articles – Page 3
-
ArticleThe art and science of drug formulation
Drug formulation is a cornerstone of modern medicine, turning raw active ingredients into consumable, effective therapies. This critical phase in drug development ensures that medications are safe, effective, and user-friendly. Here Ningfeng Fiona Li, founder and CEO of VasoDynamics, explores the world of drug formulation from its foundations to exploring ...
-
NewsElucidating MDLC’s molecular features
The study’s results indicate that spatial sequencing of mixed-type breast cancers could inform personalised treatment.
-
ArticleThe power of big data to advance genomics into clinical care
The integration of genomics into patient care will lead to more precise, personalised treatments. In this Q&A, Hylton Kalvaria, Chief Commercial Officer of Helix, explains how the Helix Research Network is creating a large-scale clinicogenomics dataset to advance research into molecular and genetic determinants of disease risk and drug response. ...
-
NewsPredicting persistent taxane-induced peripheral neuropathy
Researchers have developed a prediction model to ascertain breast cancer survivors’ risk of persistent taxane-induced peripheral neuropathy.
-
ArticleHow MMR-deficient colorectal cancers regulate their growth
Understanding how MMR-deficient colorectal cancers drive tumour growth and avoid immune detection could pave the way for personalised cancer medicine.
-
NewsPredicting pancreatic cancer metastasis
Molecular, cellular and metabolic analyses of liver biopsies identified markers that may predict subsequent metastasis of pancreatic cancer.
-
NewsEpigenetic dysregulation mechanism in Crohn’s disease discovered
Intestinal epithelial organoids highlight a pathway implicated in CD, named major histocompatibility complex (MHC)-I.
-
NewsIdentification of functional sex differences in nociceptors
A new study reveals that pain management could be greatly improved by considering patient sex as fundamental.
-
ArticleWomen in Stem with Joanne Kanaan
Introducing Joanne Kanaan, CEO and co-founder of the French startup Omini. To meet the new challenges of decentralised and personalised healthcare, Omini is developing a multiplex blood testing platform for outpatient management using a new patented biosensor technology. Joanne obtained a PhD in biochemistry and biophysics from the Ecole ...
-
NewsProteogenomics: finding targets for never-smoker lung cancer
Through multi-omics analysis, researchers find that oestrogen signalling could be a target for never-smoker lung cancer cases.
-
ArticleLeveraging ADCs in precision oncology strategy
In this Q&A, senior leaders at Caris Life Sciences discuss how the company is advancing precision medicine by integrating ADCs into patient-specific cancer treatment plans, focusing on novel target discovery through comprehensive molecular profiling and clinico-genomic data.
-
NewsModelling the blood-brain barrier with organoids
The world’s first generation of human BBB organoids from hPSCs accurately replicated features of cerebral cavernous malformation.
-
NewsNew first trimester screening algorithm for preeclampsia
The screening model combines maternal history, ultrasound data and several tests for blood markers to enable personalised treatment.
-
WhitepaperPoster: Assays for DDX3, DDX5, DDX17, RIG-I, and MDA5
A panel of HTS assays was developed using the Transcreener platform to accelerate the development of selective helicase inhibitors.
-
WhitepaperPoster: Assays for PRMT5, MLL4, METTL3/14, & NSP14
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
-
ArticleBiomarker identification in the realm of rare diseases
In this Q&A, Debiopharm’s Principal Scientist Dr Luke Piggott defines the critical requirement of biomarkers for identifying rare diseases. He illuminates how AI-enhanced approaches are accelerating the drug discovery process, particularly regarding clinical trial enrolment, and the breakthroughs he hopes to see in the future.
-
NewsDiscovery of over 100 genomic loci linked to hypertension
The study’s findings explain the genetic differences in people’s blood pressure, which could lead to personalised medicine approaches.
-
ArticleUnlocking the potential of antibody drug conjugates
Zymeworks’ Dr Paul Moore, Dr Raffaele Colombo and Dr Jamie Rich discuss how advancements in ADCs are redefining cancer treatment. They elucidate the innovative strategies that are being developed to improve drug stability and how personalised medicine approaches are optimising outcomes for individual cancer patients, offering new hope across several ...
-
NewsExplaining uveal melanoma’s resistance to conventional immunotherapies
Researchers have developed a new tool called ‘Uveal Melanoma Immunogenic Score’ to predict which patients will respond to adoptive therapy.
-
NewsDeveloping precision medicine for gestational diabetes
Researchers have identified that gestational diabetes is associated with a deficit in placental expression of IGFBP1.